ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to,or have contraindication to or who are intolerant to other systemic therapies including ciclosporin,methotrexate and psoralen plus u.v (puva).

ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen plus u.v (puva).

ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab

ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תרכיז להכנת תמיסה לאינפוזיה - ustekinumab 5 mg / 1 ml - ustekinumab

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

ישראל - עברית - Ministry of Health

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

ישראל - עברית - Ministry of Health

novartis israel ltd - secukinumab - תמיסה להזרקה - secukinumab 150 mg/ml - secukinumab

ישראל - עברית - Ministry of Health

neopharm ltd, israel - bimekizumab - תמיסה להזרקה - bimekizumab 160 mg / 1 ml - bimekizumab

ישראל - עברית - Ministry of Health

novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab

ישראל - עברית - Ministry of Health

novartis israel ltd - secukinumab - אבקה להכנת תמיסה לזריקה - secukinumab 150 mg/dose - secukinumab